Journal
BLOOD
Volume 117, Issue 12, Pages 3453-3459Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-08-300715
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL092125] Funding Source: Medline
Ask authors/readers for more resources
Antiphospholipid syndrome is characterized by thrombosis, recurrent fetal loss, and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti-beta(2)-glycoprotein-1 (anti-beta(2)-GP1) antibodies. Although anti-beta(2)-GP1 antibodies have been documented as a biomarker for diagnosis of antiphospholipid syndrome, their direct role in the pathogenesis of thrombosis is unknown. We have demonstrated using intravital microscopy that anti-beta(2)-GP1 autoantibodies purified from the sera of patients with antiphospholipid syndrome complicated by thrombosis greatly amplify thrombus size after laser-induced vessel wall injury in live mice. Anti-beta(2)-GP1 autoantibodies from 3 patients with antiphospholipid syndrome were affinity-purified using human beta(2)-GP1 bound to agarose. The effects of purified anti-beta(2)GP1 IgG autoantibodies, of anti-beta(2)-GP1-depleted IgG, and of IgG from normal human sera on thrombus formation were measured in mice after arterial injury in the cremaster muscle. Before injury, purified anti-beta(2)-GP1 IgG autoantibodies, anti-beta(2)-GP1 antibody-depleted IgG, or IgG from normal human sera were infused. Increasing amounts of purified anti-beta(2)-GP1 autoantibodies increased thrombus size in a dose-dependent manner, whereas neither anti-beta(2)-GP1 antibody-depleted IgG nor IgG from normal serum affected thrombus size. These results indicate that anti-beta(2)-GP1 IgG autoantibodies in antiphospholipid syndrome patient sera are not only a marker of antiphospholipid syndrome but are directly involved in the pathogenesis of thrombosis. (Blood. 2011; 117(12): 3453-3459)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available